Navigation Links
Uroplasty To Present At The JMP Securities Healthcare Conference
Date:7/5/2012

MINNEAPOLIS, July 5, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that Susan Holman, Chief Operating Officer, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy at the JMP Securities Healthcare Conference at 1:30 pm ET on Thursday, July 12, 2012 at the Peninsula New York Hotel in Manhattan.

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://wsw.com/webcast/jmp18/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
4. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
6. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
7. Medical Imaging Information Systems Market to 2017 - Replacement of Legacy Systems and Advances in Software Present Growth Opportunities
8. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
9. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... -- Shire plc (LSE: SHP, NASDAQ: ... Officer, will present at the Deutsche Bank 41st Annual Health ... Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... Presentations and Webcasts section of Shire,s Investor website at ... available on this same website for approximately 90 days. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 ... ... manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention which ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):